Coya Therapeutics, Inc. Financials
This page shows Coya Therapeutics, Inc. (COYA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash-rich but revenue-light, Coya is using equity-funded liquidity to support an expanding research program.
Revenue reached$7.9M in FY2025, yet R&D alone consumed$16.7M , so the business still behaves like a development platform rather than a self-funding commercial operation. More subtly, operating cash burn stayed near the prior year even as the accounting loss deepened, meaning reported earnings weakened faster than actual cash use.
The balance sheet is built for runway: cash of
This runway is being extended by external financing, not by the underlying business. FY2025 financing inflow of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Coya Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Coya Therapeutics, Inc. has an operating margin of -283.9%, meaning the company retains $-284 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -485.4% the prior year.
Coya Therapeutics, Inc.'s revenue surged 123.6% year-over-year to $7.9M, reflecting rapid business expansion. This strong growth earns a score of 58/100.
Coya Therapeutics, Inc. carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.50, Coya Therapeutics, Inc. holds $8.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Coya Therapeutics, Inc. generates a -49.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -37.6% the prior year.
Coya Therapeutics, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Coya Therapeutics, Inc. generates $0.51 in operating cash flow (-$10.7M OCF vs -$21.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Coya Therapeutics, Inc. generated $7.9M in revenue in fiscal year 2025. This represents an increase of 123.6% from the prior year.
Coya Therapeutics, Inc.'s EBITDA was -$22.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 30.8% from the prior year.
Coya Therapeutics, Inc. reported -$21.2M in net income in fiscal year 2025. This represents a decrease of 42.6% from the prior year.
Coya Therapeutics, Inc. earned $-1.27 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 29.6% from the prior year.
Cash & Balance Sheet
Coya Therapeutics, Inc. held $46.8M in cash against $0 in long-term debt as of fiscal year 2025.
Coya Therapeutics, Inc. had 21M shares outstanding in fiscal year 2025. This represents an increase of 25.3% from the prior year.
Margins & Returns
Coya Therapeutics, Inc.'s operating margin was -283.9% in fiscal year 2025, reflecting core business profitability. This is up 201.5 percentage points from the prior year.
Coya Therapeutics, Inc.'s net profit margin was -267.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 151.6 percentage points from the prior year.
Coya Therapeutics, Inc.'s ROE was -49.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 11.7 percentage points from the prior year.
Capital Allocation
Coya Therapeutics, Inc. invested $16.7M in research and development in fiscal year 2025. This represents an increase of 41.0% from the prior year.
COYA Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $251K-93.7% | $4.0M+11.1% | $3.6M+2078.4% | $164K-36.6% | $258K | N/A | $0-100.0% | $3.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $4.1M-17.1% | $4.9M+69.4% | $2.9M-20.4% | $3.7M-29.7% | $5.2M | N/A | $2.2M-51.3% | $4.6M |
| SG&A Expenses | $3.8M+15.7% | $3.3M+27.9% | $2.6M-12.1% | $2.9M+7.2% | $2.7M | N/A | $2.2M+6.3% | $2.1M |
| Operating Income | -$7.6M-26.7% | -$6.0M-147.9% | -$2.4M+62.1% | -$6.4M+16.4% | -$7.7M | N/A | -$4.5M-37.5% | -$3.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $0 |
| Net Income | -$7.2M-26.2% | -$5.7M-169.8% | -$2.1M+65.3% | -$6.1M+16.6% | -$7.3M | N/A | -$4.0M-39.1% | -$2.9M |
| EPS (Diluted) | $-0.32 | N/A | $-0.13+63.9% | $-0.36+18.2% | $-0.44 | N/A | $-0.26-36.8% | $-0.19 |
COYA Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $53.3M+6.6% | $50.0M+55.9% | $32.0M-4.2% | $33.5M-12.9% | $38.4M-13.4% | $44.3M+24.7% | $35.6M-11.0% | $39.9M |
| Current Assets | $53.3M+6.7% | $49.9M+55.9% | $32.0M-4.2% | $33.4M-12.9% | $38.4M-13.4% | $44.3M+24.8% | $35.5M-11.0% | $39.9M |
| Cash & Equivalents | $50.7M+8.3% | $46.8M+66.5% | $28.1M-5.5% | $29.8M-16.2% | $35.5M-7.3% | $38.3M+23.4% | $31.1M-15.1% | $36.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.3M-37.9% | $6.9M+45.5% | $4.8M-7.5% | $5.1M+2.1% | $5.0M+5.6% | $4.8M+34.7% | $3.5M-24.4% | $4.7M |
| Current Liabilities | $3.5M-39.6% | $5.9M+60.1% | $3.7M-18.5% | $4.5M+3.7% | $4.3M+13.5% | $3.8M+64.9% | $2.3M-39.4% | $3.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $49.0M+13.8% | $43.0M+57.7% | $27.3M-3.6% | $28.3M-15.2% | $33.4M-15.7% | $39.6M+23.6% | $32.0M-9.2% | $35.3M |
| Retained Earnings | -$69.2M-11.6% | -$62.0M-10.1% | -$56.3M-3.9% | -$54.1M-12.7% | -$48.0M-17.9% | -$40.7M-7.7% | -$37.8M-11.9% | -$33.8M |
COYA Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.2M-516.5% | -$1.0M+10.9% | -$1.1M+80.4% | -$5.8M-104.1% | -$2.8M-17.4% | -$2.4M+55.9% | -$5.5M-19.7% | -$4.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$885K-36.4% | -$649K | N/A | N/A | N/A | $0 | $0 | $0 |
| Financing Cash Flow | $11.0M-46.0% | $20.3M+106231.5% | $19K | $0-100.0% | $19K-99.8% | $9.7M+17305.4% | -$56K-101.1% | $5.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
COYA Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -3042.1%-2889.8pp | -152.3%-84.0pp | -68.3%+3852.2pp | -3920.5%-943.6pp | -2976.9% | N/A | N/A | -94.5% |
| Net Margin | -2869.6%-2725.5pp | -144.2%-84.8pp | -59.4%+3665.8pp | -3725.2%-891.8pp | -2833.3% | N/A | N/A | -84.4% |
| Return on Equity | -14.7%-1.5pp | -13.3%-5.5pp | -7.8%+13.8pp | -21.5%+0.4pp | -21.9% | N/A | -12.6%-4.4pp | -8.2% |
| Return on Assets | -13.5%-2.1pp | -11.4%-4.8pp | -6.6%+11.6pp | -18.2%+0.8pp | -19.0% | N/A | -11.3%-4.1pp | -7.2% |
| Current Ratio | 15.02+6.5 | 8.50-0.2 | 8.73+1.3 | 7.43-1.4 | 8.84-2.7 | 11.59-3.7 | 15.31+4.9 | 10.43 |
| Debt-to-Equity | 0.09-0.1 | 0.16-0.0 | 0.170.0 | 0.18+0.0 | 0.15+0.0 | 0.120.0 | 0.11-0.0 | 0.13 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Coya Therapeutics, Inc.'s annual revenue?
Coya Therapeutics, Inc. (COYA) reported $7.9M in total revenue for fiscal year 2025. This represents a 123.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Coya Therapeutics, Inc.'s revenue growing?
Coya Therapeutics, Inc. (COYA) revenue grew by 123.6% year-over-year, from $3.6M to $7.9M in fiscal year 2025.
Is Coya Therapeutics, Inc. profitable?
No, Coya Therapeutics, Inc. (COYA) reported a net income of -$21.2M in fiscal year 2025, with a net profit margin of -267.1%.
What is Coya Therapeutics, Inc.'s EBITDA?
Coya Therapeutics, Inc. (COYA) had EBITDA of -$22.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Coya Therapeutics, Inc.'s operating margin?
Coya Therapeutics, Inc. (COYA) had an operating margin of -283.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Coya Therapeutics, Inc.'s net profit margin?
Coya Therapeutics, Inc. (COYA) had a net profit margin of -267.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Coya Therapeutics, Inc.'s return on equity (ROE)?
Coya Therapeutics, Inc. (COYA) has a return on equity of -49.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Coya Therapeutics, Inc.'s operating cash flow?
Coya Therapeutics, Inc. (COYA) generated -$10.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Coya Therapeutics, Inc.'s total assets?
Coya Therapeutics, Inc. (COYA) had $50.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Coya Therapeutics, Inc. spend on research and development?
Coya Therapeutics, Inc. (COYA) invested $16.7M in research and development during fiscal year 2025.
What is Coya Therapeutics, Inc.'s current ratio?
Coya Therapeutics, Inc. (COYA) had a current ratio of 8.50 as of fiscal year 2025, which is generally considered healthy.
What is Coya Therapeutics, Inc.'s debt-to-equity ratio?
Coya Therapeutics, Inc. (COYA) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Coya Therapeutics, Inc.'s return on assets (ROA)?
Coya Therapeutics, Inc. (COYA) had a return on assets of -42.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Coya Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Coya Therapeutics, Inc. (COYA) had $46.8M in cash against an annual operating cash burn of $10.7M. This gives an estimated cash runway of approximately 52 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Coya Therapeutics, Inc.'s Piotroski F-Score?
Coya Therapeutics, Inc. (COYA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Coya Therapeutics, Inc.'s earnings high quality?
Coya Therapeutics, Inc. (COYA) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Coya Therapeutics, Inc.?
Coya Therapeutics, Inc. (COYA) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.